Member access

4-Traders Homepage  >  Shares  >  Euronext Alternext  >  NEOVACS    ALNEV   FR0004032746

NEOVACS (ALNEV)

321
Delayed Quote. Delayed Euronext Alternext - 10/21 11:35:00 am
3.18 EUR   +4.95%
10/10 NEOVACS : installs a new international scientific committee in New-York
10/10 NEOVACS : Installs a new nternational scientific committee in new york
09/18 NEOVACS : 2014 half-year results
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
10/15/2014 10/16/2014 10/17/2014 10/20/2014 10/21/2014 Date
3.12(c) 2.97(c) 3.09(c) 3.03(c) 3.18 Last
92 093 245 739 88 298 52 763 87 554 Volume
-3.41% -4.81% +4.04% -1.94% +4.95% Change
More quotes
Company
Neovacs SA is a biotechnology company.It focuses on an active immunotherapy technology platform with applications in the treatment of autoimmune and inflammatory diseases and cancer.It focuses on development on two Kinoids: Tumor Necrosis Factor-Kinoid and Interferon-Kinoid.The Tumor Necrosis... 
Surperformance© rating of NEOVACS
Trading Rating : Investor Rating :
More about the company
Chart NEOVACS
Duration : Period :
NEOVACS Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 0,50 M
EBIT 2014 -8,95 M
Net income 2014 -6,88 M
Debt 2014 3,40 M
Yield 2014 -
Sales 2015 110 M
EBIT 2015 33,6 M
Net income 2015 -6,70 M
Debt 2015 76,0 M
Yield 2015 -
PER 2014 -
PER 2015 0,86
EV / Sales 2014 126x
EV / Sales 2015 1,23x
Capitalization 59,7 M
More Financials
Latest news on NEOVACS
10/10 NEOVACS : Installs a New International Scientific Committee in New York
10/10 NEOVACS : installs a new international scientific committee in New-York
10/10 NEOVACS : Installs a new nternational scientific committee in new york
10/10 NEOVACS : Installs a New International Scientific Committee in New York (DGAP Ne..
09/23 NEOVACS : will attend Société Générale's 'Healthcare & Biotechnology Conference'..
09/18 NEOVACS : 2014 half-year results (DGAP News)
09/18 NEOVACS : 2014 half-year results
06/19 NEOVACS : Miguel Sieler Head of Neovacs: "We develop a groundbreaking technology..
06/03 NEOVACS : NAMES NATHALIE THOMAS-PUJOL HEAD OF REGULATORY AFFAIRS (DGAP News)
06/03 NEOVACS : names Nathalie Thomas-Pujol as head of Regulatory Affairs
05/20 NEOVACS : to present additional data on SLE treatment at EULAR 2014
05/15 NEOVACS : to present additional data on SLE treatment at EULAR 2014
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF